頭頸部癌に対するMTX-5FU-CBDCA療法の経験 Combined MTX-5FU-CBDCA for the Treatment of Head and Neck Cancer

この論文にアクセスする

この論文をさがす

著者

抄録

Combination chemotherapy including 5FU and carboplatin (CBDCA) with methotrexate (MTX) and leucovorin (LV) as biochemical modulation was performed on patients with head and neck cancer. A total of 32 patients were treated in the order of MTX, continuous 5FU infusion and LV injection, CBDCA. 24 of the 32 patients were concurrently treated with radiation therapy. Treatment-associated toxicity was significant, including mucositis, myelosuppression and body weight losses, but they were within acceptable limits. The 5-year survival rates calculated using Kaplan-Meyer methods were 41.3%.

収録刊行物

  • 耳鼻咽喉科臨床

    耳鼻咽喉科臨床 95(1), 81-85, 2002-01-01

    The Society of Practical Otolaryngology

参考文献:  21件中 1-21件 を表示

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    10008098721
  • NII書誌ID(NCID)
    AN00107089
  • 本文言語コード
    JPN
  • 資料種別
    NOT
  • ISSN
    00326313
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ